id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2023-N-5160-0011,FDA,FDA-2023-N-5160,Labeling Requirements for Approved or Conditionally Approved New Animal Drugs; Extension of Comment Period,Proposed Rule,Extension of Comment Period,2024-05-22T04:00:00Z,2024,5,2024-05-22T04:00:00Z,,2024-05-22T15:13:20Z,2024-11229,0,0,0900006486579492
FDA-2023-N-5160-0010,FDA,FDA-2023-N-5160,Request for Extension from Generic Animal Drug Alliance (GADA),Other,Request for Extension,2024-05-20T04:00:00Z,2024,5,2024-05-20T04:00:00Z,,2024-05-20T21:52:27Z,,0,0,09000064865693ed
FDA-2023-N-5160-0007,FDA,FDA-2023-N-5160,Request for Extension from Animal Health Institute,Other,Request for Extension,2024-04-18T04:00:00Z,2024,4,2024-04-18T04:00:00Z,,2024-04-18T17:08:51Z,,0,0,09000064864d6e9d
FDA-2023-N-5160-0003,FDA,FDA-2023-N-5160,Reference 1 Preliminary Regulatory Impact Initial Regulatory Flexibility and Unfunded Mandates Reform Act Analyses 2023 Docket No FDA-2023-N-5160,Supporting & Related Material,Background Material,2024-03-12T04:00:00Z,2024,3,,,2024-03-12T16:39:29Z,,0,0,0900006486474be4
FDA-2023-N-5160-0002,FDA,FDA-2023-N-5160,Reference 9 AVMA Pet Ownership Sourcebook 2017 2018 Table S1 Fig. 2,Supporting & Related Material,Background Material,2024-03-12T04:00:00Z,2024,3,,,2024-03-12T16:39:25Z,,0,0,0900006486474be0
FDA-2023-N-5160-0001,FDA,FDA-2023-N-5160,Labeling Requirements for Approved or Conditionally Approved New Animal Drugs,Proposed Rule,Notice of Proposed Rulemaking (NPRM),2024-03-12T04:00:00Z,2024,3,2024-03-12T04:00:00Z,2024-08-10T03:59:59Z,2024-08-10T01:01:02Z,2024-04840,0,0,090000648647460c